Lotiglipron

Lotiglipron

Identifiers
IUPAC name 2-{[4-[(2S)-2-(5-chloropyridin-2-yl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl]methyl}-3-{[(2S)-oxetan-2-yl]methyl}benzimidazole-5-carboxylic acid
CAS Number	2401892-75-7
PubChem CID	146609022
ChemSpider	129109088
UNII	YI10W1K93A
ChEMBL	ChEMBL5314631
Chemical and physical data
Formula	C31H31ClN4O5
Molar mass	575.06 g·mol^−1
3D model (JSmol)	Interactive image
SMILES C[C@]1(c2ccc(Cl)cn2)Oc2cccc(C3CCN(Cc4nc5ccc(C(=O)O)cc5n4C[C@@H]4CCO4)CC3)c2O1
InChI InChI=1S/C31H31ClN4O5/c1-31(27-8-6-21(32)16-33-27)40-26-4-2-3-23(29(26)41-31)19-9-12-35(13-10-19)18-28-34-24-7-5-20(30(37)38)15-25(24)36(28)17-22-11-14-39-22/h2-8,15-16,19,22H,9-14,17-18H2,1H3,(H,37,38)/t22-,31-/m0/s1 Key:SVPYZAJTWFQTSM-UGDMGKLASA-N

Lotiglipron is a non-peptide GLP-1 receptor agonist which was under development by Pfizer as a weight loss drug.^[1] However, it was withdrawn from development in June 2023, after early stage clinical trials showed elevated liver enzymes which could indicate potential for liver toxicity.^[2]

See also

• Danuglipron
• Orforglipron

References

1. US 10676465, Aspnes GE, et al., "GLP-1 receptor agonists and uses thereof", issued 9 June 2020, assigned to Pfizer Inc 
2. Griffin M (26 June 2023). "Pfizer Shares Drop After It Halts Development of Obesity Drug Due to Safety Concerns". Time.